Based on the provided sources, there is no direct information regarding updates to the Lipitor management strategy. The sources focus on different aspects of Lipitor, such as its patent status, its use in cardiovascular disease management, and potential drug interactions with other medications.
The first source, DrugPatentWatch, provides information about the patent status of Lipitor, indicating that the drug's patent expired in 2011. This information suggests that Lipitor is now available as a generic medication, which may have implications for its management strategy.
The second source, a book chapter from the National Center for Biotechnology Information, discusses the use of Lipitor in managing cardiovascular disease. It provides an overview of the drug's mechanism of action, its effectiveness, and potential side effects. However, it does not mention any recent updates to the management strategy.
The third source, the COVID-19 Treatment Guidelines from the National Institutes of Health, mentions Lipitor in the context of potential drug interactions with ritonavir-boosted nirmatrelvir (Paxlovid), a medication used for the treatment of COVID-19. This source highlights the importance of monitoring lipid levels when Lipitor is co-administered with ritonavir-boosted nirmatrelvir due to potential drug interactions.
In conclusion, based on the provided sources, there is no specific information regarding recent updates to the Lipitor management strategy. It is important to consult with healthcare professionals or refer to updated medical guidelines for the most current information on Lipitor's management strategy.
 DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/LIPITOR
 National Center for Biotechnology Information: https://www.ncbi.nlm.nih.gov/books/NBK430779/
 COVID-19 Treatment Guidelines - National Institutes of Health: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/